PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21225244-0	2011	The effects of acute and chronic nadolol treatment on beta2AR signaling in HEK293 cells.	Nadolol	33-40	adrenoceptor beta 2	Homo sapiens	54-61	
15595859-7	2004	Zonal displacement chromatography using CGP 12177A as the marker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilized beta(2)-AR retained its ability to specifically bind these compounds.	Nadolol	105-112	adrenoceptor beta 2	Homo sapiens	163-173	
24144049-6	2013	All experiments were performed in the presence of nadolol (a beta(1)/beta(2)-adrenoceptor antagonist).	Nadolol	50-57	adrenoceptor beta 2	Homo sapiens	69-89	
21225244-7	2011	A 5-min treatment with NAD decreased forskolin-stimulated phosphorylation at the beta(2)AR PKA site Ser 262 while a 24-h treatment with NAD increased it.	Nadolol	23-26	adrenoceptor beta 2	Homo sapiens	81-90	
21225244-10	2011	Chronic NAD treatment therefore increases cellular cAMP levels by mechanisms that include the upregulation of beta(2)AR and G(alpha)s. This effect may explain in part the beneficial effects of chronic nadolol treatment on airway contractility.	Nadolol	8-11	adrenoceptor beta 2	Homo sapiens	110-119	
21225244-10	2011	Chronic NAD treatment therefore increases cellular cAMP levels by mechanisms that include the upregulation of beta(2)AR and G(alpha)s. This effect may explain in part the beneficial effects of chronic nadolol treatment on airway contractility.	Nadolol	201-208	adrenoceptor beta 2	Homo sapiens	110-119	
8755668-4	1996	In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline produced consistent negative inotropic effects.	Nadolol	19-26	adrenoceptor beta 2	Homo sapiens	41-59	
21225244-4	2011	In this study, we examined the effects of nadolol on beta(2)AR levels and signaling components downstream of the beta(2)AR using a line of HEK293 cells expressing human beta(2)ARs.	Nadolol	42-49	adrenoceptor beta 2	Homo sapiens	53-62	
21225244-5	2011	Chronic treatment with NAD increased beta(2)AR protein levels and decreased receptor degradation, consistent with receptor stabilization by the inverse agonist.	Nadolol	23-26	adrenoceptor beta 2	Homo sapiens	37-46